Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History GOSS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics GOSS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Gossamer Bio Inc

GOSS
Current price
1.37 USD -0.04 USD (-2.84%)
Last closed 1.44 USD
ISIN US38341P1021
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 327 314 880 USD
Yield for 12 month +65.84 %
1Y
3Y
5Y
10Y
15Y
GOSS
21.11.2021 - 28.11.2021

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California. Address: 3115 Merryfield Row, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.61 USD

P/E ratio

Dividend Yield

Financials GOSS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures GOSS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+114 701 000 USD

Last Year

Current Quarter

+9 889 000 USD

Last Quarter

+9 379 000 USD

Current Year

+114 701 000 USD

Last Year

-4 385 000 USD

Current Quarter

+9 889 000 USD

Last Quarter

+9 379 000 USD
EBITDA -54 190 000 USD
Operating Margin TTM -372.23 %
Price to Earnings
Return On Assets TTM -12.68 %
PEG Ratio
Return On Equity TTM -500.57 %
Wall Street Target Price 7.61 USD
Revenue TTM 124 590 000 USD
Book Value -0.028 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM 124 590 000 USD
Earnings per share -0.25 USD
Diluted Eps TTM -0.25 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -41.13 %

Stock Valuation GOSS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.18
Price Sales TTM 2.63
Enterprise Value EBITDA -0.39
Price Book MRQ 2.66

Technical indicators GOSS

For 52 weeks

0.66 USD 1.55 USD
50 Day MA 1.09 USD
Shares Short Prior Month 10 540 492
200 Day MA 1.01 USD
Short Ratio 6.71
Shares Short 11 082 536
Short Percent 5.19 %